The National Institute for Health Research's Clinical Research Network maintains an active list of more than 800 clinicians—practicing in oncology, gastroenterology, endocrinology, and dermatology—who are interested in delivering trials of biosimilar medicines.
On the heels of revelations that the United Kingdom will not participate in the European Union’s new Clinical Trial Regulation (CTR) after Brexit, the National Institute for Health Research (NIHR) is attempting to keep biosimilar developers interested in conducting trials in the United Kingdom.
Divya Chadha Manek, head of business development for NIHR, wrote in an editorial at PharmaTimes that there is no better place to conduct a clinical trial of a biosimilar than the National Health Service (NHS). “Clinical studies, including real-world evidence studies, will continue to play a crucial role in the biosimilars boom. And what better place to run them than within the NHS in the [United Kingdom,]” wrote Manek.
Click to read more about biosimilars and the NHS.
According to Manek, the NIHR’s Clinical Research Network maintains an active list of more than 800 clinicians—practicing in oncology, gastroenterology, endocrinology, and dermatology—who are interested in delivering trials of biosimilar medicines.
Furthermore, the NIHR has launched an online resource, “Focus on Biosimilars,” that offers information for biosimilar developers on running a clinical trial in the NHS. The website includes resources related to the NIHR Study Support Service, a free service to the industry that offers a “flexible package of support” to help with site identification, delivery optimization, study setup, and performance monitoring.
It remains to be seen whether biosimilar makers will find NIHR’s offers tempting enough to compensate for the fact that the United Kingdom will become a more complex regulatory environment post-Brexit. Because the United Kingdom will not be eligible to participate in the upcoming CTR once it is no longer an EU member state, any developer seeking to conduct a clinical trial with sites in the European Union and the United Kingdom will have to apply separately to the European Medicines Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency for approval. Furthermore, researchers in the United Kingdom will not have access to the EMA’s online portal and database that will form the single point for submitting and accessing trial information throughout the European Union.
Meanwhile, the EMA continues to feel the strain of Brexit; the European Parliament’s Committee on the Environment, Public Health, and Food Safety has issued an opinion to the Committee on Budgets that says that, due to the EMA’s increased workload resulting from Brexit-related activities, the agency requires additional resources. The committee has asked Parliament to add funds and staff for a limited period so that the EMA can “retain the critical knowledge and skills necessary to continue to carry out its tasks effectively and to resume currently postponed activities.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.